A New Indication for Esketamine Nasal Spray (Spravato)

Date: September 21, 2020 Issue #:  1607Summary:  Esketamine (Spravato– Janssen), an intranasal N-methyl-D-aspartate (NMDA) receptor antagonist that was previously approved by the FDA for treatmentresistant depression,1 has now been approved for treatment of depressive symptoms in adults with major depressive disorder (MDD) and acute suicidal ideation or behavior. E sketamine is the S-enantiomer of the anesthetic ketamine (Ketalar, and generics). It is the first drug to be approved for this indication. Most clinical trials of antidepressants have excluded patients with acute suicidal ideation.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Source Type: research